Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) shares were up 1.4% during trading on Friday . The stock traded as high as $2.13 and last traded at $2.11. Approximately 14,156 shares were traded during trading, a decline of 60% from the average daily volume of 35,198 shares. The stock had previously closed at $2.08.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, June 26th.
Check Out Our Latest Report on Alpha Tau Medical
Alpha Tau Medical Price Performance
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last released its earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. As a group, research analysts predict that Alpha Tau Medical Ltd. will post -0.5 earnings per share for the current year.
Hedge Funds Weigh In On Alpha Tau Medical
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. USAdvisors Wealth Management LLC acquired a new stake in shares of Alpha Tau Medical in the 1st quarter worth approximately $30,000. Aptus Capital Advisors LLC grew its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Financial Guidance Group Inc. grew its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Telemus Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth approximately $89,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth approximately $176,000. Institutional investors and hedge funds own 2.65% of the company’s stock.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Recommended Stories
- Five stocks we like better than Alpha Tau Medical
- How to Start Investing in Real Estate
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- The Most Important Warren Buffett Stock for Investors: His Own
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.